Skip to main content
. 2012 Jan 17;109(5):1631–1636. doi: 10.1073/pnas.1115980109

Fig. 5.

Fig. 5.

DKK3-producing tolerant Des CD8 T cells are sufficient to mediate tolerance. (A) Dkk3−/−. Des.KKb mice were treated on days −5 and −3 with 0.5 mg anti-CD4 (GK1.5) and 0.5 mg anti-CD8 (53.6.7) depleting antibodies. At the time of T-cell transfer (day 0) less than 10% of the original CD4 and CD8 T cells was left in the blood of the treated mice. Purified CD8 T cells (105) either from day 12 thymectomized Des.KKb.Rag2−/− mice or from day 12 TCR8 mice were transferred. One day later, mice were inoculated s.c. with 2 × 105 P815.Kb.B7 tumor cells. (B) Kinetics of tumor growth in recipients of Des.KKb (Left) and TCR8 (Right) T cells. One (n = 7) of two independent experiments is shown. (C) Cumulative data of both experiments showing percentage of tumor-bearing mice (Left) (P < 0.05, Fisher's exact test) and tumor size (Right) of TCR8 and Des.KKb recipients (mean ± SEM, P < 0.01; n = 13). (D) Dkk3−/−. Des.KKb mice were treated and obtained CD8 T cells from day 12 thymectomized Des.KKb.Rag2−/− mice as in A. In addition, these mice received 1 mg of either anti-Dkk3 or isotype control antibody i.p. at day 0 followed by 0.5 mg antibody every third day. Cumulative data of two independent experiments show percentage of tumor-bearing mice (Left) (P < 0.05, Fisher's exact test) and tumor size (Right) (mean ± SEM, P < 0.01; n = 12).